Resmed Inc. (RMD)

$177.61

+3.78

(+2.17%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Resmed Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 963.03M → 1.16B (in $), with an average increase of 17.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 232.5M → 208.8M (in $), with an average decrease of 3.5% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 61.0%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 54.3%

Performance

  • $176.42
    $179.68
    $177.61
    downward going graph

    0.67%

    Downside

    Day's Volatility :1.81%

    Upside

    1.15%

    downward going graph
  • $131.49
    $241.04
    $177.61
    downward going graph

    25.97%

    Downside

    52 Weeks Volatility :45.45%

    Upside

    26.32%

    downward going graph

Returns

PeriodResmed Inc.Sector (Health Care)S&P500
3 Months
0.62%
-0.7%
5.0%
6 Months
22.05%
6.6%
16.4%
1 Year
-22.01%
3.7%
20.9%
3 Years
-15.48%
14.0%
20.0%

Highlights

Market Capitalization
27.2B
Book Value
$30.47
Dividend Share
1.84
Dividend Yield
1.04%
Earnings Per Share (EPS)
6.04
PE Ratio
30.61
PEG Ratio
1.75
Wall Street Target Price
202.68
Profit Margin
19.77%
Operating Margin TTM
29.18%
Return On Assets TTM
11.19%
Return On Equity TTM
21.66%
Revenue TTM
4.5B
Revenue Per Share TTM
30.63
Quarterly Revenue Growth YOY
12.5%
Gross Profit TTM
2.4B
EBITDA
1.4B
Diluted Eps TTM
6.04
Quarterly Earnings Growth YOY
-0.07
EPS Estimate Current Year
7.41
EPS Estimate Next Year
8.18
EPS Estimate Current Quarter
1.79
EPS Estimate Next Quarter
1.85

Analyst Recommendation

Buy
    64%Buy
    35%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Resmed Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
12
Hold
6
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 14.12%

Current $177.61
Target $202.68

Company Financials

FY18Y/Y Change
Revenue
2.3B
↑ 13.23%
Net Income
315.6M
↓ 7.8%
Net Profit Margin
13.49%
↓ 3.07%
FY19Y/Y Change
Revenue
2.6B
↑ 11.38%
Net Income
404.6M
↑ 28.2%
Net Profit Margin
15.52%
↑ 2.03%
FY20Y/Y Change
Revenue
3.0B
↑ 13.44%
Net Income
621.7M
↑ 53.65%
Net Profit Margin
21.02%
↑ 5.5%
FY21Y/Y Change
Revenue
3.2B
↑ 8.11%
Net Income
474.5M
↓ 23.67%
Net Profit Margin
14.84%
↓ 6.18%
FY22Y/Y Change
Revenue
3.6B
↑ 11.93%
Net Income
779.4M
↑ 64.26%
Net Profit Margin
21.78%
↑ 6.94%
FY23Y/Y Change
Revenue
4.2B
↑ 18.02%
Net Income
897.6M
↑ 15.15%
Net Profit Margin
21.25%
↓ 0.53%
Q3 FY22Q/Q Change
Revenue
950.3M
↑ 3.89%
Net Income
210.5M
↑ 7.9%
Net Profit Margin
22.15%
↑ 0.83%
Q4 FY22Q/Q Change
Revenue
1.0B
↑ 8.78%
Net Income
224.9M
↑ 6.86%
Net Profit Margin
21.76%
↓ 0.39%
Q1 FY23Q/Q Change
Revenue
1.1B
↑ 8.04%
Net Income
232.5M
↑ 3.37%
Net Profit Margin
20.82%
↓ 0.94%
Q2 FY23Q/Q Change
Revenue
1.1B
↑ 0.46%
Net Income
229.7M
↓ 1.22%
Net Profit Margin
20.47%
↓ 0.35%
Q3 FY23Q/Q Change
Revenue
963.0M
↓ 14.17%
Net Income
219.4M
↓ 4.46%
Net Profit Margin
22.78%
↑ 2.31%
Q4 FY23Q/Q Change
Revenue
1.2B
↑ 20.74%
Net Income
208.8M
↓ 4.84%
Net Profit Margin
17.96%
↓ 4.82%
FY18Y/Y Change
Total Assets
3.1B
↓ 11.66%
Total Liabilities
1.0B
↓ 33.37%
FY19Y/Y Change
Total Assets
4.1B
↑ 34.07%
Total Liabilities
2.0B
↑ 102.55%
FY20Y/Y Change
Total Assets
4.6B
↑ 11.68%
Total Liabilities
2.1B
↑ 2.7%
FY21Y/Y Change
Total Assets
4.7B
↑ 3.07%
Total Liabilities
1.8B
↓ 11.86%
FY22Y/Y Change
Total Assets
5.1B
↑ 7.78%
Total Liabilities
1.7B
↓ 5.83%
FY23Y/Y Change
Total Assets
6.8B
↑ 32.49%
Total Liabilities
2.6B
↑ 51.1%
Q3 FY22Q/Q Change
Total Assets
5.2B
↑ 1.6%
Total Liabilities
1.7B
↑ 0.55%
Q4 FY22Q/Q Change
Total Assets
6.7B
↑ 28.94%
Total Liabilities
2.9B
↑ 68.4%
Q1 FY23Q/Q Change
Total Assets
6.7B
↑ 0.57%
Total Liabilities
2.8B
↓ 5.33%
Q2 FY23Q/Q Change
Total Assets
6.8B
↑ 0.56%
Total Liabilities
2.6B
↓ 5.74%
Q3 FY23Q/Q Change
Total Assets
6.7B
↓ 0.16%
Total Liabilities
2.5B
↓ 5.01%
Q4 FY23Q/Q Change
Total Assets
6.9B
↑ 2.44%
Total Liabilities
2.4B
↓ 2.7%
FY18Y/Y Change
Operating Cash Flow
505.0M
↑ 21.97%
Investing Cash Flow
-101.8M
↑ 24.34%
Financing Cash Flow
-1.0B
↑ 290.58%
FY19Y/Y Change
Operating Cash Flow
459.1M
↓ 9.1%
Investing Cash Flow
-1.1B
↑ 956.44%
Financing Cash Flow
580.6M
↓ 156.55%
FY20Y/Y Change
Operating Cash Flow
802.3M
↑ 74.76%
Investing Cash Flow
-179.9M
↓ 83.28%
Financing Cash Flow
-317.3M
↓ 154.64%
FY21Y/Y Change
Operating Cash Flow
736.7M
↓ 8.17%
Investing Cash Flow
-158.5M
↓ 11.9%
Financing Cash Flow
-764.6M
↑ 140.99%
FY22Y/Y Change
Operating Cash Flow
351.1M
↓ 52.34%
Investing Cash Flow
-229.9M
↑ 45.09%
Financing Cash Flow
-128.4M
↓ 83.21%
FY23Y/Y Change
Operating Cash Flow
693.3M
↑ 97.44%
Investing Cash Flow
-1.2B
↑ 404.46%
Financing Cash Flow
422.9M
↓ 429.44%
Q3 FY22Q/Q Change
Operating Cash Flow
44.7M
↓ 43.81%
Investing Cash Flow
-58.8M
↑ 6.45%
Financing Cash Flow
-41.9M
↓ 172.84%
Q4 FY22Q/Q Change
Operating Cash Flow
128.6M
↑ 188.02%
Investing Cash Flow
-1.0B
↑ 1645.42%
Financing Cash Flow
932.9M
↓ 2327.56%
Q1 FY23Q/Q Change
Operating Cash Flow
282.6M
↑ 119.66%
Investing Cash Flow
-28.1M
↓ 97.26%
Financing Cash Flow
-279.6M
↓ 129.97%
Q2 FY23Q/Q Change
Operating Cash Flow
237.4M
↓ 15.97%
Investing Cash Flow
-1.2B
↑ 4026.97%
Financing Cash Flow
-188.6M
↓ 32.54%
Q3 FY23Q/Q Change
Operating Cash Flow
286.3M
↑ 20.57%
Investing Cash Flow
-149.0M
↓ 87.16%
Financing Cash Flow
-151.1M
↓ 19.86%

Technicals Summary

Sell

Neutral

Buy

Resmed Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Resmed Inc.
Resmed Inc.
-8.97%
22.05%
-22.01%
-15.48%
75.2%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-4.7%
35.81%
38.95%
38.38%
112.57%
Becton, Dickinson And Company
Becton, Dickinson And Company
-2.32%
-10.48%
-8.43%
-10.33%
1.9%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-4.64%
0.62%
4.23%
19.12%
238.38%
Alcon Ag
Alcon Ag
-6.1%
7.94%
11.1%
7.08%
42.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Resmed Inc.
Resmed Inc.
30.61
30.61
1.75
7.41
0.22
0.11
0.01
30.47
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
75.26
75.26
7.13
6.25
0.15
0.08
NA
37.77
Becton, Dickinson And Company
Becton, Dickinson And Company
52.86
52.86
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
48.1
48.1
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
40.62
40.62
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Resmed Inc.
Resmed Inc.
Buy
$27.2B
75.2%
30.61
19.77%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$134.2B
112.57%
75.26
25.24%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.8B
1.9%
52.86
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.8B
238.38%
48.1
20.12%
Alcon Ag
Alcon Ag
Buy
$39.5B
42.78%
40.62
10.3%

Institutional Holdings

  • Vanguard Group Inc

    12.06%

  • BlackRock Inc

    8.33%

  • State Street Corporation

    4.28%

  • Geode Capital Management, LLC

    2.34%

  • FMR Inc

    1.72%

  • Amvescap Plc.

    1.32%

Corporate Announcements

  • Resmed Inc. Dividends March,2024

    In the quarter ending March,2024. Resmed Inc. has declared dividend of $0.48

    Read More

Company Information

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Organization
Resmed Inc.
Employees
0
CEO
Mr. Michael J. Farrell BE, MBA, SM
Industry
Health Technology

Discover More

FAQs